ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million
21 Oct, 2021
– Century Therapeutics, a Philadelphia, PA-based cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, closed a $160m Series C financing.
– The round was led by Casdin Capital and brought together a syndicate of new investors including Fidelity Management & Research LLC, the Federated Hermes Kauffmann Funds, RA Capital, Logos Capital, OrbiMed, Marshall Wace, Qatar Investment Authority, Avidity Partners, and Octagon Capital.
– Eli Casdin, Founder and Chief Investment Officer of Casdin Capital will be joining the Century Therapeutics Board of Directors.